The development of therapeutic antibodies has grown over the last several years. Most of
the recombinant monoclonal antibodies (mAbs) produced by mammalian cells are …

Monoclonal antibody therapeutics are a heterogeneous mixture of glycoforms. Multiple
methods exist for defining the glycan composition and relative abundance of species …

Therapeutic monoclonal antibodies (mAbs), immunoglobulins, have been efficiently used in
the treatment of many diseases, such as cancer, inflammatory and cardiovascular diseases …

Monoclonal antibodies have been used increasingly as therapeutic agents to target various
diseases. Although most monoclonal antibodies have only one N-linked glycosylation site in …

N-glycan analysis of recombinant monoclonal antibodies (mAbs) usually requires the
removal of oligosaccharides by PNGase F followed by 2-AB labeling, normal phase high …

During the development of recombinant monoclonal antibody (rMAb) drugs, glycosylation
receives particular focus because changes in the attached glycans can have a significant …

The N-linked glycosylation of four lots of a marketed human therapeutic monoclonal
antibody (mAb) was assessed by three orthogonal chromatographic methods and a …

The number of therapeutic monoclonal antibodies (mAbs) is growing rapidly due to their
widespread use for treating various diseases and health conditions. Assessing the …

Monoclonal antibodies (mAbs), are one of the most important protein drugs have attracted
increasing attention. However, the pharmacokinetics of mAbs has not been fully investigated …

Glycosylation which plays a crucial role in the pharmacological properties of therapeutic
monoclonal antibodies (MAbs) is influenced by several factors like production systems …